Significance of Anti-retinal Autoantibodies in Cancer-associated Retinopathy with Gynecological Cancers
|Grazyna Adamus1*, Dongseak Choi2, Anitha Raghunath3 and Jade Schiffman3|
|1Ocular Immunology Laboratory, Casey Eye Institute, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA|
|2Department Public Health and Preventive Medicine, Department School of Medicine,Oregon Health & Science University, Portland, OR 97239, USA|
|3Department of Ophthalmology and Neuro-oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA|
|Corresponding Author :||Grazyna Adamus, Ph.D
Ocular Immunology Laboratory
L467AM, Oregon Health and Science University
3181 SW Sam Jackson Pk Rd
Portland, OR 97239, USA
E-mail: [email protected]
|Received: October 07, 2013; Accepted: November 18, 2013; Published: November 25, 2013|
|Citation: Adamus G, Choi D, Raghunath A, Schiffman J (2013) Significance of Anti-retinal Autoantibodies in Cancer-associated Retinopathy with Gynecological Cancers. J Clin Exp Ophthalmol 4:307. doi:10.4172/2155-9570.1000307|
|Copyright: © 2013 Adamus G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: The presence of autoantibodies (AAbs) is the primary serological indicator of autoimmunity. Cancerassociated retinopathy (CAR) is associated with AAbs and different types of cancer. The goal of the study was to examine the profile of serum autoantibodies in women with gynecological cancers with and without paraneoplastic visual manifestation.
Methods: Retrospective studies of a cohort of 46 women with symptoms of CAR and gynecological tumors, including endometrial, cervical, ovarian, and fallopian tubes, 111 women with similar tumors without symptoms of CAR, and 60 age-matched healthy controls. Presence of serum AAbs and the identity of targeted antigens were performed by western blotting and their significance was evaluated using an Fisher’s exact test.
Results: The patients with gynecological CAR had the highest proportion of seropositivity (80%), followed by patients with gynecological cancers without CAR (61%) and healthy controls (58%). Differences in recognition frequencies were found for 17 antigens and 5 retinal antigens were frequently targeted: enolase, aldolase C, carbonic anhydrase II, recoverin and GAPDH. The occurrence of anti-glycolytic enzymes was 2-3 times more frequent in CAR and cancer patients than healthy controls. Anti-recoverin AAbs were prevalent in endometrial CAR. Anti-CAII antibodies were not significantly different between groups of women. In this cohort, cancer was diagnosed before the onset of retinopathy with latency from 2 months to 30 years. The discovery of the ovarian and endometrial cancers and manifestation of visual problems often coincided but Fallopian tube carcinoma was found after visual onset.
Conclusion: New retinal targets were identified for gynecological CAR. Each gynecological-CAR has its own autoantibody profile different from non-CAR profile, implying that a complex autoantibody signature may be more predictable for diagnosis than a singular AAb. Specific anti-retinal AAbs were most prevalent in women with CAR but their profiles were not fully distinguished from cancer controls.